Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.93 |
| ▸ | PGR | P06401 | 4/20 | 0.93 |
| ▸ | AR | P10275 | 3/20 | 0.93 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.85 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.85 |
| ▸ | SHBG | P04278 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Acetate SCHEMBL7520412 | 1.00 | HIF1A (0.93) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2679809 | 0.97 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL7419 | 0.97 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2452043 | 0.97 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL25599370 | 0.97 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL4940901 | 0.97 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL13026148 | 0.97 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2832039 | 0.96 | HIF1A (0.98) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL11238411 | 0.96 | HIF1A (0.98) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL11238414 | 0.96 | HIF1A (0.98) | HIF1APGRARSERPINA6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299366-A1 | MOLECULARLY IMPRINTED POLYMER NANOPARTICLES COMPATIBLE WITH BIOLOGICAL SAMPLES AND PREPARATION METHOD THEREOF | NANKAI UNIVERSITY (CN) | 2015-10-22 | — | — | US | claimed |
| JP-2011529904-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110269699-A1 | CANCER THERAPY | PETER MACCALLUM CANCER CENTRE (AU) | 2011-11-03 | — | — | US | claimed |
| EP-2309854-A1 | ACCELERATED THERAPY | Gloucester Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| CN-116761893-A | Method for transducing immune cells | 艾洛基治疗公司 | 2023-09-15 | — | — | CN | disclosed |
| US-10053531-B2 | Molecularly imprinted polymer nanoparticles compatible with biological samples and preparation method thereof | NANKAI UNIVERSITY (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20150299366-A1 | MOLECULARLY IMPRINTED POLYMER NANOPARTICLES COMPATIBLE WITH BIOLOGICAL SAMPLES AND PREPARATION METHOD THEREOF | NANKAI UNIVERSITY (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20130102533-A1 | ALBUMIN FUSION PROTEINS | HUMAN GENOME SCIENCES, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20120046442-A1 | ROMIDEPSIN SOLID FORMS AND USES THEREOF | APTUIT, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110269699-A1 | CANCER THERAPY | PETER MACCALLUM CANCER CENTRE (AU) | 2011-11-03 | — | — | US | disclosed |
| EP-2381964-A1 | SYNTHESIS OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS | Creabilis S.a. (LU) | 2011-11-02 | — | — | EP | disclosed |
| EP-2309854-A1 | ACCELERATED THERAPY | Gloucester Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| CN-1250562-C | Process for preparing hydrocortisone acetate | SHANDONG XINHUA PHARMACEUTICAL (CN) | 2006-04-12 | — | — | CN | disclosed |
| US-20050244931-A1 | Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders | HUMAN GENOME SCIENCES, INC. | 2005-11-03 | — | — | US | disclosed |
| CN-1603333-A | Process for preparing hydrocortisone acetate | SHANDONG XINHUA PHARMACEUTICAL (CN) | 2005-04-06 | — | — | CN | disclosed |
| US-20040146893-A1 | Nucleotide sequences coding heterologous polypeptide for use in diagnosis and treatment of nervous system, cell proliferative, inflammatory and autoimmune diseases; wound healing agents | HUMAN GENOME SCIENCES, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2001010907-A9 | THERAPEUTIC POLYPEPTIDES AND METHODS FOR USING SAME | UNIV MARYLAND BIOTECH INST (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046442-A1 | ROMIDEPSIN SOLID FORMS AND USES THEREOF | RDX, RPLP1, SFPQ | NR3C1 3092/4885HIF1A 4546/4885PGR 1261/4885 |
| US-20110269699-A1 | CANCER THERAPY | BCL3, BCL2, BCL2L2 | NR3C1 1252/4885HIF1A 1989/4885PGR 118/4885 |
| US-20050244931-A1 | Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders | VEGFA, SSB, ALB | NR3C1 3027/4885HIF1A 1036/4885PGR 3621/4885 |
| US-20130102533-A1 | ALBUMIN FUSION PROTEINS | ALB, FABP1, HDGF | NR3C1 3057/4885HIF1A 708/4885PGR 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.